Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (593)	9/3/2008 10:11:58 AM
From: BulbaMan	Respond to of 671

Tuck: Protiva, mentioned in article, merged with Tekmira (Yahoo symbol is TKM.TO). And Tekmira claims to be able to handle the RNAi off-target problem with its RNAi delivery technology. Here's Tekmira's PR on the study: biz.yahoo.com

To: tuck who wrote (593)	9/3/2008 2:29:38 PM
From: Ian@SI	Respond to of 671

Clearly, getting off target immune responses would almost certainly be undesirable most, if not all, of the time. After reflecting further about the PR, would the pt or Dr care, if an on target response cured the disease whether or not it was a direct result of the siRNA or the result of an immune reaction to that siRNA? Seems to me a successful tx is more than acceptable regardless of the precise pathway to that cure. And a cure via an Immune response could well be more lasting.